International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(14), P. 7959 - 7959
Published: July 21, 2024
Esophageal
cancer
ranks
the
seventh
in
incidence
and
sixth
death.
squamous
cell
carcinoma
(ESCC)
accounts
for
approximately
90%
of
total
cases
esophageal
cancer.
Chemotherapy
is
most
effective
drug-based
method
treatment
However,
severe
side
effects
traditional
chemotherapy
limit
its
efficacy.
Targeted
can
deliver
chemotherapeutic
drugs
to
cells
specifically
kill
these
with
reduced
effects.
In
work,
bivalent
aptamer-DNA
carrier
(BAD)
was
designed
by
using
an
ESCC
cell-specific
aptamer
as
recognition
molecule
a
GC
base-rich
DNA
sequence
drug
carrier.
With
doxorubicin
(Dox)
drugs,
aptamer-DNA-Dox
conjugate
(BADD)
constructed
targeted
killing
cells.
Firstly,
truncated
A2(35)
retained
binding
ability
obtained
through
optimization
intact
A2(80)
used
fuse
sequences
constructing
BAD
simple
hybridization.
The
results
gel
electrophoresis
flow
cytometry
analysis
showed
that
successfully
had
stronger
affinity
than
monovalent
A2(35).
Then,
loaded
Dox
construct
BADD
noncovalent
intercalation.
fluorescence
spectra
assays
bind
target
strongly.
Confocal
imaging
further
displayed
be
internalized
into
release
Dox.
CCK-8
assays,
Calcein
AM/PI
staining,
wound
healing
demonstrated
cells,
but
not
control
Our
demonstrate
developed
selectively
offering
potentially
strategy
ESCC.
ACS Synthetic Biology,
Journal Year:
2025,
Volume and Issue:
14(1), P. 21 - 40
Published: Jan. 6, 2025
The
field
of
healthcare
diagnostics
is
navigating
complex
challenges
driven
by
evolving
patient
demographics
and
the
rapid
advancement
new
technologies
worldwide.
In
response
to
these
challenges,
biosensors
offer
distinctive
advantages
over
traditional
diagnostic
methods,
such
as
cost-effectiveness,
enhanced
specificity,
adaptability,
making
their
integration
with
point-of-care
(POC)
platforms
more
feasible.
recent
years,
aptasensors
have
significantly
evolved
in
capabilities
through
emerging
microfluidics,
Clustered
Regularly
Interspaced
Short
Palindromic
Repeats
(CRISPR)
systems,
wearable
devices,
machine
learning
(ML),
driving
progress
precision
medicine
global
solutions.
Moreover,
advancements
not
only
improve
accuracy
but
also
hold
potential
revolutionize
early
detection,
reduce
costs,
outcomes,
especially
resource-limited
settings.
This
Account
examines
key
advancements,
focusing
on
how
scientific
breakthroughs,
including
artificial
intelligence
(AI),
improved
sensitivity
precision.
Additionally,
has
enabled
real-time
monitoring
data
analysis,
fostering
advances
personalized
healthcare.
Furthermore,
commercialization
aptasensor
could
increase
availability
clinical
settings
support
use
widespread
solutions
for
health
challenges.
Hence,
this
review
discusses
technological
improvements,
practical
uses,
prospects
while
surrounding
standardization,
validation,
interdisciplinary
collaboration
application.
Finally,
ongoing
efforts
address
are
ensure
that
can
be
effectively
implemented
diverse
systems.
Exploration,
Journal Year:
2024,
Volume and Issue:
4(4)
Published: Feb. 9, 2024
Cornea
is
the
major
barrier
to
drug
delivery
eye,
which
results
in
low
bioavailability
and
poor
efficacy
of
topical
eye
treatment.
In
this
work,
we
first
select
cornea-binding
aptamers
using
tissue-SELEX
on
pig
cornea.
The
top
two
abundant
aptamers,
Cornea-S1
Cornea-S2,
could
bind
cornea,
their
ACS Omega,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 4, 2025
Purpose:
Locked
nucleic
acid
(LNA)-modified
anti-microRNAs
have
been
demonstrated
to
target
mesenchymal
stem
cells
(MSCs)
treat
bone
diseases.
However,
the
"off-target"
effect
limits
its
clinical
application.
Methods:
We
selected
specific
aptamer
M4
of
MSCs
and
employed
three-way
junction
(3WJ)
as
core
scaffold
construct
nanoparticles
(3WJ-M4-LNA)
for
delivery
anti-miRNA
138.
Results:
Our
results
suggested
that
3WJ-M4-LNA
nanoparticles,
not
3WJ-M4
or
3WJ-LNA,
can
specifically
deliver
MSCs,
resulting
in
significant
inhibition
miRNA
138
expression.
experiment
further
confirmed
promote
MSCs'
osteogenic
differentiation
by
activating
ERK1/2
pathway.
In
vivo,
promoted
formation
improved
microarchitecture
rabbit
osteoporosis
models.
Conclusions:
These
indicate
3WJ
could
develop
a
therapeutic
strategy
osteoporosis.
Expert Review of Proteomics,
Journal Year:
2025,
Volume and Issue:
22(1), P. 11 - 18
Published: Jan. 2, 2025
Introduction
Identifying
early
risks
of
developing
Alzheimer's
disease
(AD)
is
a
major
challenge
as
the
number
patients
with
AD
steadily
increases
and
requires
innovative
solutions.
Current
molecular
diagnostic
modalities,
such
cerebrospinal
fluid
(CSF)
testing
positron
emission
tomography
(PET)
imaging,
exhibit
limitations
in
their
applicability
for
large-scale
screening.
In
recent
years,
there
has
been
marked
shift
toward
development
blood
plasma-based
tests,
which
offer
more
accessible
clinically
viable
alternative
widespread
use.
Furthermore,
advances
proteomics
technologies
have
boosted
an
interest
identifying
novel
biomarkers
panels
AD-associated
proteins.
